Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi
Autor: | Jian-Hong Zhong, Xiao-Ling Luo, Zhe Guo, Le-Qun Li, Ye-Bin Pang, Ning-Fu Peng, Bang-De Xiang, Chao Ou |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Male medicine.medical_specialty Pathology Cirrhosis Carcinoma Hepatocellular Liver Stem Cell Gene Expression Gastroenterology Pathogenesis 03 medical and health sciences 0302 clinical medicine Text mining Internal medicine medicine Biomarkers Tumor Humans CD90 Neoplasm Invasiveness Neoplasm Metastasis Neoplasm Staging business.industry Liver Neoplasms General Medicine Bile Duct Tumor Middle Aged medicine.disease Immunohistochemistry Treatment Outcome 030220 oncology & carcinogenesis Hepatocellular carcinoma Neoplastic Stem Cells 030211 gastroenterology & hepatology Female Bile Ducts Stem cell Neoplasm Grading business Biomarkers |
Zdroj: | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(5) |
ISSN: | 1423-0380 |
Popis: | The aim of this study was to analyze the clinicopathological characteristics and expression of liver stem cell markers of hepatocellular carcinoma (HCC) involving bile duct tumor thrombi (BDTT). A total of 35 patients with HCC and BDTT in a consecutive series of HCC patients who underwent surgical treatment were studied retrospectively and compared with 916 patients without BDTT from the same series. Clinicopathological characteristics, overall survival (OS), and tumor expression of liver stem cell markers CD133, CD90, EpCAM, CK19, VEGF, and C-kit were compared between the two patient groups. Analysis was performed for the entire patient groups as well as for 35 pairs of patients with or without BDTT matched by propensity score. HCC patients with BDTT tended to have smaller tumors than those without BDTT, as well as a higher probability of having poorly differentiated tumor, Child-Pugh class B, liver cirrhosis, and microvascular invasion. Tumor tissue in patients with BDTT showed significantly higher expression rates of all liver stem cell markers examined. OS was significantly lower for patients with BDTT at 1 year (69 vs 84 %), 3 years (37 vs 64 %), and 5 years (20 vs 55 %) (P |
Databáze: | OpenAIRE |
Externí odkaz: |